NYC Health + Hospitals Bellevue Completes 200th Minimally Invasive Heart Valve Replacement

NYC Health + Hospitals/Bellevue announced on June 9, 2026, that its cardiovascular team successfully completed the 200th Transcatheter Aortic Valve Replacement (TAVR) procedure. This milestone comes just over three years after the program’s inception in March 2023, representing a significant expansion of high-tech cardiac services within the nation’s largest municipal healthcare system. TAVR is a minimally invasive alternative to traditional open-heart surgery, designed specifically for patients with severe aortic stenosis—a condition where the heart's aortic valve narrows and restricts blood flow. The procedure involves threading a replacement valve through a catheter, typically through the femoral artery in the leg, allowing surgeons to repair the heart without a chest incision. For the patient population at Bellevue, many of whom present with advanced comorbidities that would make traditional surgery life-threatening, this technology provides a critical pathway to recovery. The 200th patient, 53-year-old Nestor Morales, serves as a representation of the program's focus on complex, high-risk cases that require multidisciplinary intervention. By reaching this volume, Bellevue establishes itself as a primary hub for structural heart innovation within the public safety-net framework, ensuring that advanced medical technology is not restricted to private, high-resource institutions.

Advanced Cardiac Intervention for Queens Resident Nestor Morales

The 200th patient to undergo TAVR at Bellevue, Nestor Morales, illustrates the complex medical journeys often managed by the New York City public health system. A resident of Queens, Morales first sought care at NYC Health + Hospitals/Elmhurst in June 2025 according to NYC Health + Hospitals. At the time, he suffered from severe shortness of breath and leg swelling, symptoms that were eventually linked to a trio of serious conditions: liver disease, heart failure, and severe aortic stenosis. Because of the complexity of his cardiac disease, Elmhurst clinicians coordinated a transfer to Bellevue’s specialized structural heart program. Before the procedure could occur, the Bellevue Heart Team identified a significant anatomical hurdle. Evaluation revealed that Morales faced a high risk for coronary obstruction, a complication where the new valve might accidentally block the blood supply to the heart muscle. To mitigate this, the team utilized a specialized technique known as Bioprosthetic/Native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction (BASILICA). Dr. Rafael Harari led the team in performing the BASILICA-augmented TAVR in April, and Morales was able to return home only one day after the surgery. At a follow-up appointment in late May, Morales noted that the intervention provided him with a new lease on life, resolving the chronic fatigue and breathing difficulties that had previously sidelined him.

The Evolution of the Bellevue Structural Heart Program Since 2023

Bellevue Hospital’s TAVR program was launched in March 2023 to address a gap in access for New York’s underserved populations. Historically, advanced structural heart procedures were concentrated in private academic medical centers, which can present barriers for patients relying on Medicaid or those without insurance. Since launching, the program has scaled quickly to meet demand, reaching the 200-procedure mark in roughly 39 months. This growth indicates a high level of integration between the various departments within the hospital. According to NYC Health + Hospitals, the program utilizes a multidisciplinary Heart Team approach, bringing together specialists from cardiology, advanced heart failure, cardiac surgery, and cardiac imaging. This collaborative model is essential for managing the types of patients Bellevue typically sees: individuals who often arrive with advanced stages of disease due to a lack of routine primary care. The program’s ability to move from a pilot phase to a high-volume center reflects a systemic investment in specialized equipment and staff training. By providing post-operative follow-up and dedicated structural heart clinic evaluations, Bellevue ensures that the care does not end when the patient leaves the operating room, which is vital for long-term survival in populations with limited social supports.

Bridging the Health Equity Gap in Advanced Cardiovascular Care

The achievement at Bellevue serves as a focal point for the discussion surrounding health equity in New York City. Often, the latest medical advancements reach municipal hospitals years after they become standard at private institutions. However, the TAVR program at Bellevue suggests a shift in how the New York City public health system views its role in delivering specialized care. CEO Eric Wei emphasized that health equity requires that the best available treatments be accessible regardless of a patient's ability to pay. For patients with aortic stenosis, the alternative to TAVR is often remaining on medical management, which has a poor prognosis for those with severe symptoms. By offering a minimally invasive option, Bellevue reduces the physical and financial burden on patients who cannot afford long recovery periods away from work or family responsibilities. Dr. Norma Keller, Chief of Cardiology at Bellevue, noted that the program is essential for patients who traditionally face barriers to specialty care. The data from the first 200 cases suggests that the outcomes at this public institution are comparable to those at private centers, even though the Bellevue patient population generally carries a higher burden of secondary illnesses. This success challenges the assumption that safety-net hospitals cannot maintain the rigorous infrastructure required for high-stakes cardiac interventions.

Technical Complexity and the Use of the BASILICA Technique

One of the most technically demanding aspects of the 200th case was the requirement for the BASILICA technique. This procedure involves using an electrified wire to split an existing heart valve leaflet before the new valve is implanted. This ensures that when the new TAVR valve expands, it does not push the old tissue against the openings of the coronary arteries, which would cause a massive heart attack. The implementation of such specialized maneuvers at a public hospital indicates a high level of clinical sophistication. Dr. Rafael Harari, who serves as the Director of the Structural Heart Program, highlighted that the ability to perform these complex procedures is what distinguishes Bellevue as a referral center for the entire municipal system. As noted by NYC Health + Hospitals, the partnership between Elmhurst and Bellevue was critical for the Morales case, showing that the system is capable of moving patients to the specific facility that matches their clinical needs. The BASILICA technique is not common in all TAVR centers, further positioning Bellevue as a leader in managing "hostile" anatomy and high-risk patients. This technical proficiency is a necessary component of treating a public hospital population that often presents with anatomical variations or advanced disease states not typically seen in younger or healthier patient cohorts.

Economic and Operational Shift for Public Safety-Net Systems

From an operational standpoint, the success of the TAVR program at Bellevue suggests a sustainable model for public healthcare systems. While TAVR hardware is expensive, the total cost of care is often offset by the reduction in hospital stay duration. Patients like Nestor Morales, who was discharged only 24 hours after a complex heart procedure, free up hospital beds much faster than those undergoing traditional open-heart surgery, which requires several days in the intensive care unit and a week or more in the hospital. For a facility like Bellevue, which manages over 100,000 emergency room visits and half a million outpatient visits annually, bed turnaround is a critical metric. Furthermore, the ability of a public hospital to perform 200 successful TAVR procedures changes the referral patterns within the city. Instead of higher-acuity cardiac patients being siphoned off to private equity-backed or private non-profit systems, the public system can retain these patients, maintaining the continuity of care through its own network of primary care clinics. This retention is vital for the financial health of the municipal system, as it allows the organization to participate in the full spectrum of modern medicine. The volume of 200 cases also provides the necessary data for the hospital to pursue further certifications and potentially expand into other transcatheter therapies for mitral or tricuspid valve disease.

Future Directions for Cardiovascular Excellence at Bellevue

Looking ahead, the milestone of 200 TAVRs sets the stage for the next phase of cardiovascular services at Bellevue. The hospital, which is the nation’s oldest public medical facility, has functioned as a Level I Trauma Center and a major referral hub for decades. The maturity of the TAVR program allows the institution to focus on further reducing barriers to pre-operative screening. Many potential candidates for valve replacement are currently undiagnosed in the community, often mistaking their shortness of breath for normal aging or lung issues. Future initiatives likely involve expanded screening at community health centers throughout the five boroughs to identify patients earlier in their disease progression. As the system continues to monitor the long-term outcomes of its first 200 patients, the data will likely be used to advocate for more resources in the cardiovascular space. The success of the partnership between Elmhurst and Bellevue serves as a blueprint for how other hospitals within the NYC Health + Hospitals network can collaborate. By centralizing high-complexity procedures at Excellence Centers like Bellevue while maintaining local follow-up at community hospitals, the system can maximize efficiency without sacrificing patient convenience. The 200th procedure is not just a numerical capstone but a validation of the strategy to keep public healthcare at the cutting edge of medical technology.